Importance Parkinson disease is the second most common neurodegenerative disease
worldwide. Although no available therapies alter the underlying neurodegenerative process …

Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …

Abstract Interpretation of clinical trials comparing different drug regimens for Parkinson's
disease (PD) is complicated by the different dose intensities used: higher doses of levodopa …

Dopaminergic medications used in the treatment of patients with Parkinson's disease are
associated with motor and non-motor behavioural side-effects, such as dyskinesias and …

Methods We used Canadian and American national guidelines to inform this review, in
addition to published systematic reviews that were known to us. We identified additional …

Context An association between dopamine-replacement therapies and impulse control
disorders (ICDs) in Parkinson disease (PD) has been suggested in preliminary studies …

Parkinson disease (PD) is an age-related neurodegenerative disorder that affects as many
as 1–2% of persons aged 60 years and older. With the aging of the population, the …

Impulse control disorders (ICDs), including compulsive gambling, buying, sexual behavior,
and eating, are a serious and increasingly recognized psychiatric complication in …

Patients suffering from Parkinson's disease (PD) will typically experience a range of motor
and nonmotor symptoms during the course of their illness, each of which will affect a …

Nonmotor symptoms (NMS) are increasingly recognized as important and neglected aspects
of Parkinson's disease (PD). We evaluated their relative frequency and comparative impact …